March 2024
1. BENNETT SD, Cross JH, Chowdhury K, Ford T, et al
   Clinical effectiveness of the psychological therapy Mental Health Intervention for Children with Epilepsy in addition to usual care compared with assessment-enhanced usual care alone: a multicentre, randomised controlled clinical trial in the UK.
   Lancet. 2024 Mar 7:S0140-6736(23)02791-5. doi: 10.1016/S0140-6736(23)02791.
   

   >> Share

   
   
2. GANDY M, Dudeney J
   Integrated psychological care for youth with epilepsy.
   Lancet. 2024 Mar 7:S0140-6736(24)00309-X. doi: 10.1016/S0140-6736(24)00309.
   

   >> Share

   
   November 2023
3. YUE J, Zhang G, Zhao D
   Resective epilepsy surgery in a 55-year-old man with focal cortical dysplasia and drug-resistant epilepsy.
   Lancet. 2023;402:1786-1787.
   

   >> Share

   
   
4. GEDEON E, Henderson M, Leyland AH, Allik M, et al
   Association between care experience and mental health hospitalisation among children in Scotland, with a focus on chronic conditions (CHiCS): a population-wide longitudinal study using administrative data.
   Lancet. 2023;402 Suppl 1:S5.
   

   >> Share

   
   July 2023
5. ASADI-POOYA AA, Brigo F, Lattanzi S, Blumcke I, et al
   Adult epilepsy.
   Lancet. 2023 Jul 14:S0140-6736(23)01048-6. doi: 10.1016/S0140-6736(23)01048.
   

   >> Share

   
   April 2023
6. HIRAKAWA H, Terao T
   A strange smell and visions in a 45-year-old man with focal epilepsy.
   Lancet. 2023;401:1458.
   

   >> Share

   
   March 2023
7. WEATHERALD J, Humbert M
   Ordinal outcomes add value to clinical trials - Authors' reply.
   Lancet. 2023;401:995.
   

   >> Share

   
   October 2021
8. SEN A, Hallab A, Cross JH, Sander JW, et al
   Optimising epilepsy care throughout the Afghan refugee crisis.
   Lancet. 2021;398:1563.
   

   >> Share

   
   April 2021
9. MARSON A, Burnside G, Appleton R, Smith D, et al
   The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
   Lancet. 2021;397:1375-1386.
   

   >> Share

   
   
10. MARSON A, Burnside G, Appleton R, Smith D, et al
    The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
    Lancet. 2021;397:1363-1374.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share